Neostem Inc. (NBS, Financial) filed Quarterly Report for the period ended 2012-09-30.
Neostem, Inc. has a market cap of $94.7 million; its shares were traded at around $0.6375 with and P/S ratio of 1.3.
Processing and Storage Services, representing revenues from our oncology, cord blood, and adult stem cell banking activities, were approximately $0.6 million for the three months ended September 30, 2012 compared to $0.4 million for the three months ended September 30, 2011, representing an increase of approximately $0.1 million or 29%. The increase
For the three months ended September 30, 2012, total cost of revenues were approximately $3.7 million compared to $1.9 million for the three months ended September 30, 2011, representing an increase of $1.9 million or 98%. Overall, gross profit for the three months ended September 30, 2012 was $0.7 million compared to $0.3 million for the three months ended September 30, 2011, representing an increase of approximately $0.4 million or 140% .
Processing and Storage Services were approximately $2.0 million for the nine months ended September 30, 2012 compared to $1.2 million for the nine months ended September 30, 2011, representing an increase of approximately $0.8 million or 62%. The increase is primarily attributable to increased revenue from our oncology stem cell processing service. Additionally, we added hospital clients during 2012 as more hospitals have begun to outsource their oncology stem cell processing.
For the nine months ended September 30, 2012, total cost of revenues were approximately $9.4 million compared to $5.3 million for the nine months ended September 30, 2011, representing an increase of $4.1 million or 77%. Overall, gross profit for the nine months ended September 30, 2012 was $2.1 million compared to $0.5 million, representing an increase of approximately $1.6 million or 327% .
Read the The complete Report
Neostem, Inc. has a market cap of $94.7 million; its shares were traded at around $0.6375 with and P/S ratio of 1.3.
Highlight of Business Operations:
For the three months ended September 30, 2012, total revenues were approximately $4.4 million compared to $2.2 million for the three months ended September 30, 2011, representing an increase of $2.3 million or 104%. Revenues for period were comprised of the following (in thousands):Processing and Storage Services, representing revenues from our oncology, cord blood, and adult stem cell banking activities, were approximately $0.6 million for the three months ended September 30, 2012 compared to $0.4 million for the three months ended September 30, 2011, representing an increase of approximately $0.1 million or 29%. The increase
For the three months ended September 30, 2012, total cost of revenues were approximately $3.7 million compared to $1.9 million for the three months ended September 30, 2011, representing an increase of $1.9 million or 98%. Overall, gross profit for the three months ended September 30, 2012 was $0.7 million compared to $0.3 million for the three months ended September 30, 2011, representing an increase of approximately $0.4 million or 140% .
Processing and Storage Services were approximately $2.0 million for the nine months ended September 30, 2012 compared to $1.2 million for the nine months ended September 30, 2011, representing an increase of approximately $0.8 million or 62%. The increase is primarily attributable to increased revenue from our oncology stem cell processing service. Additionally, we added hospital clients during 2012 as more hospitals have begun to outsource their oncology stem cell processing.
For the nine months ended September 30, 2012, total cost of revenues were approximately $9.4 million compared to $5.3 million for the nine months ended September 30, 2011, representing an increase of $4.1 million or 77%. Overall, gross profit for the nine months ended September 30, 2012 was $2.1 million compared to $0.5 million, representing an increase of approximately $1.6 million or 327% .
Read the The complete Report
